SCHEMBL7006730

SCHEMBL7006730

CN(C)c1cccc(C(=O)NCC2Cc3cccc4c(=O)[nH]c(=O)n(c34)C2)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
POLB P06746 2/20 0.44
TP53 P04637 2/20 0.44
HSD17B10 Q99714 2/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44
NAMPT P43490 1/20 0.43
DRD2 P14416 6/20 0.41
DRD3 P35462 6/20 0.41
CHRM3 P20309 1/20 0.41
LMNA P02545 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GFER P55789 1/20 0.38
HTR1A P08908 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7003217 0.91 DRD2 (0.41) KDM4ESMN1; SMN2ALDH1A1NAMPTDRD2
SCHEMBL7002574 0.87 CTSL (0.44) KDM4ENAMPTDRD2DRD3HTR1A
SCHEMBL7004553 0.84 DRD2 (0.40) NAMPTDRD2DRD3HTR1A
SCHEMBL7006541 0.83 DRD2 (0.42) DRD2DRD3HTR1A
SCHEMBL7004878 0.82 USP30 (0.42) KDM4ENAMPTDRD2DRD3HTR1A
SCHEMBL7003016 0.82 THRB (0.42) KDM4EALDH1A1TSHRNAMPTLMNA
SCHEMBL7008105 0.82 MTNR1A (0.50) DRD2DRD3HTR1A
Hydrochloric Acid SCHEMBL7001226 0.81 HDAC3 (0.41) NAMPTDRD2DRD3HTR1A
SCHEMBL7005337 0.80 HTR1A (0.38) DRD2DRD3HTR1A
SCHEMBL7005191 0.77 PARP1 (0.42) KDM4EPOLBHSD17B10ALDH1A1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105118-A1 Tricyclic quinazolinediones SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-06-05 US disclosed
EP-1288216-A1 TRICYCLIC QUINAZOLINEDIONES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105118-A1 Tricyclic quinazolinediones PARP1, PARP11, PARP2 KDM4E 2332/4885SMN1; SMN2 2318/4885POLB 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.